Bexagliflozin
Författaruppgift saknas
Tidskrift saknas · review PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för bexagliflozin. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
22 träffarEfficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
Xie L, Han J, Cheng Z, Liu D, Liu J, Xu C, Sun W, Li Q, Bian F, Zhang W, Chen J, Zhu Q, Thurber TK, Lock JP, Zhang B.
J Diabetes · clinical trial, phase iii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/1753-0407.13526Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.
McMurray JJV, Solomon SD, Lock JP, Massaro JM, Zhu F, Zhou W, Skali H, Lewis EF, Freeman MW, Halvorsen YC.
Diabetes Obes Metab · meta-analysis; journal article · DOI 10.1111/dom.15394Bexagliflozin.
Giruzzi M, Worthey A.
Clin Diabetes · research-article; journal article · DOI 10.2337/cd23-0085Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Dholariya S, Dutta S, Singh R, Parchwani D, Sonagra A, Kaliya M.
Expert Opin Pharmacother · meta-analysis; systematic review; journal article · DOI 10.1080/14656566.2023.2269854A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes.
Cowart K, Coon S, Carris NW.
Ann Pharmacother · review; journal article · DOI 10.1177/10600280231190443Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1683bCardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors.
Frąk W, Hajdys J, Radzioch E, Szlagor M, Młynarska E, Rysz J, Franczyk B.
Biomedicines · review-article; review; journal article · DOI 10.3390/biomedicines11072085Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Halvorsen YD, Conery AL, Lock JP, Zhou W, Freeman MW.
Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.15192Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.
Hadd MJ, Bienhoff SE, Little SE, Geller S, Ogne-Stevenson J, Dupree TJ, Scott-Moncrieff JC.
J Vet Intern Med · research-article; journal article; clinical trial, veterinary · DOI 10.1111/jvim.16730Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Pasqualotto E, Figueiredo Watanabe JM, Gewehr DM, da Silva Maintinguer R, van de Sande-Lee S, de Araujo GN, Leal FS, Pinheiro CEA.
Diabetes Obes Metab · meta-analysis; systematic review; journal article · DOI 10.1111/dom.15051Bexagliflozin: First Approval.
Hoy SM.
Drugs · review; journal article · DOI 10.1007/s40265-023-01848-xA 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, Freeman MW.
Diabetes Obes Metab · randomized controlled trial; journal article · DOI 10.1111/dom.14875Meta-analysis Addressing the Cardiovascular Safety of Bexagliflozin in Patients With Type 2 Diabetes Mellitus.
Patoulias D, Dimosiari A.
Am J Cardiol · letter; meta-analysis · DOI 10.1016/j.amjcard.2022.05.005Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.
Benedict SL, Mahony OM, McKee TS, Bergman PJ.
Can J Vet Res · research-article; journal articleBexagliflozin for type 2 diabetes: an overview of the data.
Azzam O, Carnagarin R, Lugo-Gavidia LM, Nolde J, Matthews VB, Schlaich MP.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2021.1959915A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Halvorsen YD, Walford G, Thurber T, Russell H, Massaro M, Freeman MW.
Diabetes Obes Metab · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.13928Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans.
Zhang W, Li X, Ding H, Lu Y, Stilwell GE, Halvorsen YD, Welihinda A.
Xenobiotica · journal article · DOI 10.1080/00498254.2019.1654634A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Halvorsen YC, Walford GA, Massaro J, Aftring RP, Freeman MW.
Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.13833A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW.
Diabetes Obes Metab · comparative study; equivalence trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/dom.13801Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, Trescoli C, Serusclat P, Freeman MW, Halvorsen YC.
Am J Kidney Dis · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1053/j.ajkd.2019.03.417EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Zhang W, Welihinda A, Mechanic J, Ding H, Zhu L, Lu Y, Deng Z, Sheng Z, Lv B, Chen Y, Roberge JY, Seed B, Wang YX.
Pharmacol Res · journal article · DOI 10.1016/j.phrs.2011.01.001